Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: First Quarter ended 31st March 2006
Announcement Date: 27th April 2006
GSK reported a strong start to 2006, driven by top-line pharmaceutical sales growth of 10% and significant progress in its product pipeline. The results are presented under International Financial Reporting Standards (IFRS) as adopted in the EU. The company emphasizes Constant Exchange Rate (CER) growth to illustrate underlying performance.
Key Financial Metrics
| Metric | Q1 2006 (£m) | Q1 2005 (£m) | CER Growth % | Reported Growth % |
|---|---|---|---|---|
| Turnover | 5,813 | 5,036 | 10% | 15% |
| Operating Profit | 2,174 | 1,747 | 15% | 24% |
| Profit Before Tax | 2,170 | 1,711 | 17% | 27% |
| Profit After Tax | 1,530 | 1,223 | 16% | 25% |
| Earnings Per Share (EPS) | 26.5 p | 21.1 p | 17% | 26% |
| Operating Margin | 37.4% | 34.7% | - | - |
| Effective Tax Rate | 29.5% | 28.5% | - | - |
Cash Flow and Liquidity
- Operating Cash Flow: £1,782 million (Net cash inflow from operating activities).
- Net Debt: Reduced to £372 million (from £1,237 million at the beginning of the period), representing a reduction of £865 million.
- Cash and Cash Equivalents: £4,740 million at 31st March 2006.
- Share Buy-backs: Repurchased £219 million of shares in Q1 2006; expects to repurchase £1 billion for the full year.
- Dividend: First interim dividend declared at 11 pence per share (up from 10 pence in Q1 2005).
Material Changes vs. Prior Period
- Revenue Growth: Total turnover grew 10% (CER) to £5.8 billion. Pharmaceutical sales grew 10% to £5.0 billion, while Consumer Healthcare grew 6% to £768 million.
- Regional Performance: USA pharmaceutical sales drove growth with a 15% increase to £2.6 billion. International markets rose 12%. European sales grew only 1%, impacted by lower seasonal antibiotic use.
- Margin Expansion: Operating margin increased by 2.7 percentage points (reported) and 1.8 percentage points (CER). This was driven by improved cost of sales margins (due to favorable mix and a £65 million write-back of a restructuring provision for the Montrose site) and SG&A costs rising only 5% against 10% revenue growth.
- Product Performance:
- Advair/Seretide: +12% to £816 million.
- Avandia: +24% to £384 million.
- Vaccines: +44% to £366 million.
- Flonase: -27% to £131 million due to generic competition in the USA starting March 7th.
Guidance, Outlook, and Risks
Guidance and Outlook
- 2006 EPS Guidance: GSK expects earnings per share growth to be around 10% in CER terms for the full year 2006.
- Pipeline Milestones:
- Cervarix: Filed in EU and 13 international markets; 4.5-year data shows 100% efficacy against HPV 16/18.
- Tykerb: Excellent Phase III data for breast cancer received; filing expected in H2 2006.
- Trexima: Positive Phase III data for migraine; launch expected later in 2006.
- Alli: Received FDA approvable letter for OTC weight loss; approval expected H2 2006.
Risks and Contingencies
- Tax Disputes: Significant ongoing dispute with the US IRS regarding transfer pricing for Glaxo heritage products (1989-2000). Total claims amount to $4.6 billion in taxes plus $3.9 billion in interest ($8.5 billion total). Trial delayed to January 2007; decision expected in H2 2008. GSK has a tax creditor balance of £2.6 billion including provisions for these disputes.
- Legal Matters: Aggregate provision for legal and other disputes (excluding tax) is over £1.2 billion. Key issues include:
- Wellbutrin XL: Patent infringement actions by Biovail against generic manufacturers.
- Flonase: Generic entry by Roxane and Par Pharmaceuticals following the expiration of a temporary restraining order.
- Anti-trust: Litigation regarding Wellbutrin SR and Canadian importation.
- Manufacturing: The bond related to the Cidra, Puerto Rico manufacturing site has been cancelled following the meeting of all conditions.
Investor Verification Checklist
- IRS Tax Liability: Verify the status of the $8.5 billion US tax claim and the adequacy of the £2.6 billion provision.
- Flonase Generic Impact: Assess the long-term revenue impact of generic Flonase entry in the US market.
- Pipeline Execution: Monitor the regulatory filing dates and approval outcomes for Tykerb, Cervarix, and Trexima.
- Share Buy-backs: Track the execution of the remaining £781 million of the £1 billion annual buy-back program.
- Antibiotic Seasonality: Confirm if the 1% growth in European sales was purely seasonal or indicative of broader market trends.